Product Image

Contributor Information

  • Name David Lane
  • Institute Absolute Antibody ; Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details

  • Tool name: Anti-PCNA [PC10]
  • Clone: rPC10
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Recombinant
  • Conjugate: Unconjugated
  • Reactivity: Human ; Insect ; Saccharomyces
  • Host: Mouse
  • Molecular weight of the target: 36 kDa
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: Monoclonal antibody which binds a widely conserved proliferating cell nuclear antigen, present in all proliferating cells as a marker of DNA synthesis, with neoplastic diagnostic and prognostic value. Background and Research Application PCNA, also known as polymerase delta auxiliary protein, is essential for DNA replication and is involved in DNA excision and mismatch repair pathways. PCNA is required for cellular DNA synthesis, and in vitro replication of SV40 DNA. It helps to co-ordinate the leading and lagging strand synthesis at the replication fork. PCNA binds to the CDK inhibitor p21, the structure-specific endonucleases Fen1 and XPG, and DNA cytosine 5-methyltransferase (MCMT). PCNA is potentially a therapeutic target in cancer therapy and a useful marker for identifying the proliferation status of tumour tissue (i.e. relevant to prognosis). This antibody can be used to grade different neoplasms, e.g. astrocytoma. It can be of diagnostic and prognostic value. This antibody was first published in 1990 when various monoclonal antibodies for PCNA were created to characterise and understand the function of this protein within cellular DNA synthesis and proliferation.
  • Immunogen: Protein A-PCNA fusion obtained from pC2T.
  • Immunogen UniProt ID: P12004
  • Isotype: IgG2a
  • Research area: Cancer; Cell biology; Genetics

  • For Research Use Only

Target Details

  • Target: Proliferating cell nuclear antigen, (PCNA), also known as cyclin or polymerase delta accessory protein
  • Target molecular weight: 36 kDa
  • Target background: Monoclonal antibody which binds a widely conserved proliferating cell nuclear antigen, present in all proliferating cells as a marker of DNA synthesis, with neoplastic diagnostic and prognostic value. Background and Research Application PCNA, also known as polymerase delta auxiliary protein, is essential for DNA replication and is involved in DNA excision and mismatch repair pathways. PCNA is required for cellular DNA synthesis, and in vitro replication of SV40 DNA. It helps to co-ordinate the leading and lagging strand synthesis at the replication fork. PCNA binds to the CDK inhibitor p21, the structure-specific endonucleases Fen1 and XPG, and DNA cytosine 5-methyltransferase (MCMT). PCNA is potentially a therapeutic target in cancer therapy and a useful marker for identifying the proliferation status of tumour tissue (i.e. relevant to prognosis). This antibody can be used to grade different neoplasms, e.g. astrocytoma. It can be of diagnostic and prognostic value. This antibody was first published in 1990 when various monoclonal antibodies for PCNA were created to characterise and understand the function of this protein within cellular DNA synthesis and proliferation.

Application Details

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS only
  • Storage conditions: Store at -20°C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4°C

Documentation

References

  •   Zhang et al. 2018. Dev Cell. 46(4):397-409.e5. PMID: 30130530.
  •   Original hybridoma first published in Waseem et al. 1990. J Cell Sci. 96 ( Pt 1):121-9. PMID: 1695635.
  •   Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.